A multicenter phase IIb study using HLA-unmatched allogeneic placenta-derived stromal cells (PLX-PAD) for the treatment of severe critical limb ischem → ICON CLINICAL RESEARCH LIMITED

Opportunity overview

Recipient: ICON CLINICAL RESEARCH LIMITED • Role: participant • EC contribution: €625,000 • Project: PACE • Objective: PACE aims to transform the treatment of patients suffering from critical limb ischemia (CLI), a disease with high medical need, because of limited treatment opti

Pro Feature

Unlock Complete Call Dossier

Read the unredacted funding guidelines, scope, eligibility criteria, and submission instructions.

Upgrade to Pro to Read Full Call →

EU Fund Portal Signals

Is this worth the team's time?

Directional signals based on the call structure, available source text, and deadline pressure. These are not funding guarantees.

Source language: EnglishConfidence: Medium

Competition

4/ 5

Lower Competition

5 means a narrower, more approachable field. 1 means heavy competition.

Application Effort

2/ 5

Manageable

1 is straightforward. 5 means a demanding application with heavier coordination or compliance.

Why competition looks like this

Confidence: Medium

The call looks specialized, which can narrow the field of credible applicants.
TRL requirements and cross-border consortium specifications restrict eligible applicant pools.
Budget allocations indicate high proposal success probabilities for specialised applicants.

Why effort looks like this

Confidence: Low

Expect a standard proposal package with budget and supporting materials.
Submission dossier requires multi-partner budget synchronization and work package signoffs.
Administrative guidelines impose formal SME compliance declarations and financial audits.

AI Dossier Preview

Unlock Full Feasibility Intelligence & Consultant Analysis

Pro members access complete competitive breakdowns, compliance risk analyses, plain-English translations for foreign-language notices, and tailored submission checklists.

Unlock Pro Intelligence →Instant access • Cancel anytime

Consortium

Probably not required

Co-funding

Not clearly indicated

Documentation

Moderate

Deadline pressure

Closed

Eligibility scope

Narrow

Technical depth

Moderate

Eligibility

Awarded

A multicenter phase IIb study using HLA-unmatched allogeneic placenta-derived stromal cells (PLX-PAD) for the treatment of severe critical limb ischem → ICON CLINICAL RESEARCH LIMITED

Opportunity overview

Unlock Complete Call Dossier

Is this worth the team's time?

Why competition looks like this

Why effort looks like this

Unlock Full Feasibility Intelligence & Consultant Analysis

Eligibility

Application deadline

Key information

Official Application Portal

Preparation Checklist